Literature DB >> 30115657

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

George S Laszlo1, Mary E Beddoe1, Colin D Godwin2, Olivia M Bates1, Chelsea J Gudgeon1, Kimberly H Harrington1, Roland B Walter3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30115657      PMCID： PMC6355486          DOI： 10.3324/haematol.2018.202069

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Authors:  Guillaume Olombel; Estelle Guerin; Julien Guy; Jean-Yves Perrot; Florent Dumezy; Adrienne de Labarthe; Jean-Noël Bastie; Ollivier Legrand; Emmanuel Raffoux; Adriana Plesa; Orianne Wagner-Ballon; Edouard Cornet; Véronique Salaun; Claude Preudhomme; Xavier Thomas; Cécile Pautas; Sylvain Chantepie; Pascal Turlure; Sylvie Castaigne; Hervé Dombret; Jean Feuillard
Journal:  Blood       Date:  2016-02-29       Impact factor: 22.113

2.  No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Authors:  Rosemary E Gale; Teodora Popa; Melissa Wright; Naeem Khan; Sylvie D Freeman; Alan K Burnett; Nigel H Russell; Robert K Hills; David C Linch
Journal:  Blood       Date:  2017-12-11       Impact factor: 22.113

3.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jessica A Pollard; Michael Loken; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Richard Aplenc; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

4.  Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Min Zhu; Andrea Kratzer; Jessica Johnson; Chris Holland; Christian Brandl; Indrajeet Singh; Andreas Wolf; Sameer Doshi
Journal:  J Clin Pharmacol       Date:  2017-09-18       Impact factor: 3.126

Review 5.  Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  C D Godwin; R P Gale; R B Walter
Journal:  Leukemia       Date:  2017-06-13       Impact factor: 11.528

6.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jatinder K Lamba; Lata Chauhan; Miyoung Shin; Michael R Loken; Jessica A Pollard; Yi-Cheng Wang; Rhonda E Ries; Richard Aplenc; Betsy A Hirsch; Susana C Raimondi; Roland B Walter; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

7.  Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.

Authors:  George S Laszlo; Kimberly H Harrington; Chelsea J Gudgeon; Mary E Beddoe; Matthew P Fitzgibbon; Rhonda E Ries; Jatinder K Lamba; Martin W McIntosh; Soheil Meshinchi; Roland B Walter
Journal:  Oncotarget       Date:  2016-07-12

8.  Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Authors:  N Khan; R K Hills; P Virgo; S Couzens; N Clark; A Gilkes; P Richardson; S Knapper; D Grimwade; N H Russell; A K Burnett; S D Freeman
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

9.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Authors:  Sergio Amadori; Stefan Suciu; Dominik Selleslag; Franco Aversa; Gianluca Gaidano; Maurizio Musso; Luciana Annino; Adriano Venditti; Maria Teresa Voso; Carla Mazzone; Domenico Magro; Paolo De Fabritiis; Petra Muus; Giuliana Alimena; Marco Mancini; Anne Hagemeijer; Francesca Paoloni; Marco Vignetti; Paola Fazi; Liv Meert; Safaa Mahmoud Ramadan; Roel Willemze; Theo de Witte; Frédéric Baron
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

Authors:  Kimberly H Harrington; Chelsea J Gudgeon; George S Laszlo; Kathryn J Newhall; Angus M Sinclair; Stanley R Frankel; Roman Kischel; Guang Chen; Roland B Walter
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240
View more
  8 in total

1.  Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.

Authors:  Colin D Godwin; Olivia M Bates; Sae Rin Jean; George S Laszlo; Eliotte E Garling; Mary E Beddoe; Michael H Cardone; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2020-07-04

Review 2.  Evaluation of CD33 as a genetic risk factor for Alzheimer's disease.

Authors:  Steven Estus; Benjamin C Shaw; Nicholas Devanney; Yuriko Katsumata; Eileen E Press; David W Fardo
Journal:  Acta Neuropathol       Date:  2019-04-04       Impact factor: 17.088

3.  A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.

Authors:  Priyanka Nair-Gupta; Michael Diem; Dara Reeves; Weirong Wang; Robert Schulingkamp; Katrin Sproesser; Bethany Mattson; Bradley Heidrich; Mark Mendonça; Jocelin Joseph; Jocelyn Sendecki; Brad Foulk; Gerald Chu; Damien Fink; Qun Jiao; Sheng-Jiun Wu; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-03-10

Review 4.  Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.

Authors:  Yufeng Shang; Fuling Zhou
Journal:  Front Oncol       Date:  2019-09-19       Impact factor: 6.244

Review 5.  Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.

Authors:  Bo Yu; Delong Liu
Journal:  Biomark Res       Date:  2019-10-31

6.  No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Authors:  Tamara Castaño-Bonilla; Eva Barragán; Claudia Sargas; Alejandro Sanz; Lorenzo Algarra; Pilar Herrera-Puente; Raimundo García-Boyero; Manuel Barrios; David Martinez-Cuadron; Rebeca Rodriguez-Veiga; Blanca Boluda; Cristina Gil; Josefina Serrano-López; Joaquín Martínez-López; María José Sayas-Lloris; María Teresa Olave; Rosalía Riaza-Grau; Teresa Bernal-Del Castillo; María José Larrayoz; Raquel Amigo; Antonio Jiménez-Velasco; Joaquín Sánchez; Rosa Ayala; Carlos Blas; Daniel Lainez; Juana Serrano-López; Miguel A Sanz; Juan M Alonso-Domínguez; Pau Montesinos
Journal:  Dis Markers       Date:  2022-08-23       Impact factor: 3.464

7.  Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood.

Authors:  Kyra van der Pan; Sandra de Bruin-Versteeg; Daniela Damasceno; Alejandro Hernández-Delgado; Alita J van der Sluijs-Gelling; Wouter B L van den Bossche; Inge F de Laat; Paula Díez; Brigitta A E Naber; Annieck M Diks; Magdalena A Berkowska; Bas de Mooij; Rick J Groenland; Fenna J de Bie; Indu Khatri; Sara Kassem; Anniek L de Jager; Alesha Louis; Julia Almeida; Jacqueline A M van Gaans-van den Brink; Alex-Mikael Barkoff; Qiushui He; Gerben Ferwerda; Pauline Versteegen; Guy A M Berbers; Alberto Orfao; Jacques J M van Dongen; Cristina Teodosio
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

Review 8.  Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Authors:  Laurène Fenwarth; Elise Fournier; Meyling Cheok; Thomas Boyer; Fanny Gonzales; Sylvie Castaigne; Nicolas Boissel; Juliette Lambert; Hervé Dombret; Claude Preudhomme; Nicolas Duployez
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.